Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
TAPENTADOLHYDROCHLORIDE 4,7 mg/ml SAMENSTELLING overeenkomend met ; TAPENTADOL 4 mg/ml
Grunenthal B.V. De Corridor 21K 3621 ZA BREUKELEN
N02AX06
TAPENTADOLHYDROCHLORIDE 4,7 mg/ml SAMENSTELLING overeenkomend met ; TAPENTADOL 4 mg/ml
Drank
CITROENZUUR 1-WATER (E 330) ; FRAMBOZENSMAAKSTOF ; NATRIUMBENZOAAT (E 211) ; PROPYLEENGLYCOL (E 1520) ; SUCRALOSE (E 955) ; WATER, GEZUIVERD,
Oraal gebruik
Tapentadol
Hulpstoffen: CITROENZUUR 1-WATER (E 330); FRAMBOZENSMAAKSTOF; NATRIUMBENZOAAT (E 211); PROPYLEENGLYCOL (E 1520); SUCRALOSE (E 955); WATER, GEZUIVERD;
2017-08-18
Palexia 4 mg/ml oral solution 13-12-2022 NL PIL Version: 22.00-030 1 q-xx PACKAGE LEAFLET: INFORMATION FOR THE USER PALEXIA 4 MG/ML DRANK Tapentadol READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet (see section 4). WHAT IS IN THIS LEAFLET 1. What Palexia is and what it is used for 2. What you need to know before you take Palexia 3. How to take Palexia 4. Possible side effects 5. How to store Palexia 6. Contents of the pack and other information 1. WHAT PALEXIA IS AND WHAT IT IS USED FOR Tapentadol - the active substance in Palexia - is a strong painkiller which belongs to the class of opioids. Palexia is used for the treatment of moderate to severe acute pain in children from 2 years of age and _ _ in adults that can only be adequately managed with an opioid painkiller. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PALEXIA DO NOT TAKE PALEXIA • If you are allergic to tapentadol or any of the other ingredients of this medicine (listed in section 6), • If you have asthma or if your breathing is dangerously slow or shallow (respiratory depression, hypercapnia), • If you have paralysis of the gut, • If you have acute poisoning with alcohol, sleeping pills, pain relievers or other psychotropic medicines (medicines that affect mood and emotions) (see "Other medicines and Palexia"), WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Palexia, if you: • have slow or shallow breathing, • suffer from increased pressure in the brain or disturbed consciousness up to coma, • have had a head injury or brain tumors, • Lees het volledige document
Palexia 4 mg/ml oral solution 19-09-2022 NL SmPC Version 25.00 1 q-xx 1. NAME OF THE MEDICINAL PRODUCT Palexia 4 mg/ml drank 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml oral solution contains 4 mg tapentadol (as hydrochloride) Excipients with known effect Palexia 4 mg/ml oral solution contains propylene glycol, sodium benzoate and sodium. See section 4.4 For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral solution Clear, colourless solution pH 3.5 to 4.5 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Palexia is indicated for the relief of moderate to severe acute pain in children from 2 years of age and in adults, which can be adequately managed only with opioid analgesics. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The use of Palexia in children is restricted to hospital use where appropriate equipment to enable respiratory support is available. The dosing regimen should be individualised according to the severity of pain being treated, the previous treatment experience and the ability to monitor the patient. _Adults: _ Patients should start treatment with single doses of 50 mg tapentadol as oral solution administered every 4 to 6 hours. Higher starting doses may be necessary depending on the pain intensity and the patient’s previous history of analgesic requirements. On the first day of dosing, an additional dose may be taken as soon as one hour after the initial dose, if pain control is not achieved. The dose should then be titrated individually to a level that provides adequate analgesia and minimises undesirable effects under the close supervision of the prescribing physician. Total daily doses greater than 700 mg tapentadol on the first day of treatment and maintenance daily doses greater than 600 mg tapentadol have not been studied and are therefore not recommended. Palexia 4 mg/ml oral solution 19-09-2022 NL SmPC Version 25.00 2 q-xx Calculation table for Palexia 4 MG/ML oral solution: Single dose of tapentadol prescribed Volume (ml) to be administered 25 mg 6.25 ml 50 Lees het volledige document